Saideep Healthcare and Research has raised equity
Saideep Healthcare and Research Private Limited has successfully completed a fundraising. This funding will help Saideep become a leading healthcare brand, offering advanced specialties across the region. The funds from this collaboration will be used to diversify into new and complex specialties, expand infrastructure and meet the growing demand for high-quality healthcare services in Western India.
Saideep is a 260-bed multispecialty hospital based in Ahmednagar, Maharashtra, India, that has redefined healthcare delivery in the region since its inception in February 2019. This institution was founded through a collaborative effort by leading consultants in the city, who combined their expertise and resources to create a state-of-the-art facility.
Oaklins’ team in India advised the client on securing a strategic partner through an equity fundraise, and developed a strategy that led to a highly profitable exit for existing shareholders after four years.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more